Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor Arthritis Rheum. cytokines include tumour necrosis factor-alpha (TNF-), IL-1, IL-6, IL-8, interferon-gamma (IFN-) and granulocyte-macrophage colony-stimulating factor (GM-CSF) [6C8]. Among these cytokines, TNF- and IL-1 have been studied most extensively because of their actions in Bromisoval inducing the expression of other cytokines and CAM. This has been confirmed by clinical trials using anti-TNF- MoAb and IL-1 antagonists in the treatment of RA synovitis [9,10]. Furthermore, it is well established that TNF- and IL-1 stimulate gene expression of these cytokines and CAM through a signal transduction pathway leading to NF-B activation [11C16]. NF-B is an inducible cellular transcription factor present in the primordial mesenchymal cell lineage including lymphocytes, macrophages and fibroblasts Bromisoval [11,16]. NF-B regulates a wide variety of cellular genes including those associated with RA. Although NF-B is usually by no means the sole determinant for the inducible expression of these genes, it has been shown to play a significant role in inducing their expression [11C16]. It has been reported that an IB kinase is usually involved in NF-B activation by directly phosphorylating IB [17,18]. Although specific inhibitors of kinases involved in the NF-B activation cascade have yet to be identified, antioxidants such as N-acetyl-l-cysteine (NAC) [19,20] are known to block the NF-B cascade. The anti-inflammatory effects of steroids, retinoids and a variety of anti-rheumatic drugs take place by mechanisms that converge on a limited quantity of transcription factors, most notably the proinflammatory transcription factors AP-1 and NF-B [21]. Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine), a synthetic sulfhydryl (SH) compound like NAC developed as a disease-modifying anti-rheumatic drug (DMARD) for the treatment of RA, has shown clinical efficacy in RA and related arthritides [22]. In the present study we investigate the role of NF-B in cytokine production and RA using bucillamine Rabbit Polyclonal to CDK11 and NAC to block the NF-B activation pathway. MATERIALS AND METHODS Reagents Lipopolysaccharide (LPS; 055; B5; Difco, Detroit, MI), bovine type II collagen (CII; Cosmobio, Tokyo, Japan), Freund’s total adjuvant (FCA; Difco), RPMI1640 (Gibco, Rockville, MD), fetal calf serum (FCS; Gibco), HEPES (Nacalai Tasque, Tokyo, Japan), Nonidet P-40 (Nacalai Tasque), KCl (Wako, Tokyo, Japan), MgCl2 (Wako), PMSF (Wako), aprotinin (Wako), dithiothreitol (DTT; Sigma, St Louis, MO), EDTA-2Na (Dojindo, Tokyo, Japan) and NAC (Sigma) were purchased from your sources shown. Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) was synthesized by the Central Research Laboratories of Santen Pharmaceutical Co., Ltd. Cell collection and cell culture Human monocytic leukaemia cell collection THP-1 and mouse monocytic leukaemia cell collection J774.1 were obtained from the American Type Culture Collection (Rockville, MD). The cells were produced in RPMI1640 supplemented with 10% FCS and 50 m 2-mercaptoethanol. Nuclear extracts and electrophoretic mobility shift assay The cells were cultured in the presence or absence of drugs with 2 Bromisoval g/ml of LPS for 1 h and nuclear extracts were prepared as explained by Molitor [23] with minor modifications. Briefly, THP-1 cells (1 106 cells) were harvested and incubated with buffer A (10 mm HEPES pH 7.8, 10 mm KCl, 2.0 mm MgCl2, 1.0 mm DTT, 0.1 mm EDTA, 0.1 mm PMSF, 100 U/ml aprotinin) for 15 min at 4C. Nonidet P40 Bromisoval answer (final concentration 0.6%) was then added and Bromisoval the cells were centrifuged for 30 s at 12 000 < 0.05; **< 0.01 control group by Wilcoxon test. , Control; ?, bucillamine 500 mg/kg per day; ?, NAC 500 mg/kg per day. Open in a separate windows Fig. 4 Effects of bucillamine and N-acetyl-l-cysteine (NAC) on bone changes in type II collagen-induced arthritis in mice. Drugs were administered every day from the day of the second immunization. The degree of arthritis was observed every 3 days from the second immunization. Values are expressed as means s.e.m. of 9C22 animals. *< 0.05 control group by Wilcoxon test. Bucillamine 500 mg/kg per day. NAC 500 mg/kg per day. Table 4 Effects of bucillamine and N-acetyl-l-cysteine (NAC) on type II collagen (CII) antibody level.